



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

TARGETING apoptosis

Monday, 19 December 2022

Starhotels Excelsior, BOLOGNA

Organizing Secretariat



info@proeventi.it



Free Registration

www.proeventi.it

President: G. Martinelli

Chairs: G. Marconi, G. Martinelli, C. Papayannidis

Co-Chairs: C. Cerchione, A. Curti, G. Simonetti

09.00 Participant Registration

09.30 Welcome and Introduction
G. Martinelli

SESSION I

Deciphering apoptosis

Chairs: C. Papayannidis, E. Petracci

09.50 Targeting apoptosis pathways in
mutated leukemia
G. Simonetti

10.10 The BCL2/BCLx inhibitor Navitoclax in clinical
(T-ALL) experience
E. Jabbour

10.30 Targeting pyroptosis, necroptosis and
ferroptosis pathways, in cancer, leukemia and
inflammatory diseases
D. Girelli

10.50 The mitochondrial machinery
D. Cilloni

11.10 – 11.30 Coffee Break

11.30 Netosis e DNA extrusion and immunity In AML
M. Colombo

11.50 How to improve BCL2 inhibition
V. Gaidano

12.10 Targeting apoptosis: beyond Bcl-2
M. Konopleva

12.30 New evidence in "forcing" apoptosis
V. Ciminale

12.50 Panel Discussion
Discussant: L. Maurillo, R. La Starza, MT. Giaimo

13.30 Lunch

SESSION II

New therapeutic approaches to induce apoptosis SIGNALING: Present and Future

Chairs: M. Gottardi, R. Lemoli, C. Papayannidis

14.30 Special lecture: Deciphering apoptosis
M. Andreeff

14.50 BCL2 inhibitors: Venetoclax as a model
D. Cilloni

15.10 BCL2 inhibitors: Venetoclax and Decitabine or
Azacytadine alone and in combination with IDH inhibitors
as a eradication leukemia model
C. DiNardo

15.30 BCL2 inhibitors in other disease:
The Venetoclax history in MM
C. Cerchione

15.50 A live cell imaging pipeline for quantifying
mitochondrial inter-organelle interaction.
(Venetoclax/S384)
A. Hamacher-Brady

16.10 Is the Triplet combination
(Gilteritinib, Magrolimab and CD123)
a potential strategy for eradication of AML?
N. Daver

16.30 Optimizing the use of BCL2 inhibitors:
the Avalon experience
G. Marconi

16.50 BCL2 related alterations and response to therapy in
lymphoid neoplasms: IRST experience.
A. Ferrari

17.10 Panel Discussion
Discussant: S. Sica, D. Griguolo

18.00 Closing Remarks
G. Martinelli

with the unrestricted educational grant of

werfen